Abstracts Archive - Page 518 of 1683 - ATC Abstracts

2020 American Transplant Congress
Solid Organ Transplantation Using Hepatitis C Virus Positive Donor Organs for Hepatitis C Virus Negative Recipients
T. Schiff, R. Bodin, I. Lee, K. Okumura, D. C. Wolf, A. Dhand, A. L. Gass, D. Spielvogel, G. Veillette, S. Nishida, D. Glicklich, K. Wolfe, T. Diflo, H. Sogawa
New York Medical College/ Westchester Medical Center, Valhalla, NY
*Purpose: To determine the effects of transplanting an HCV-positive solid organ to an uninfected patient who is on the transplant waiting list and might otherwise…
2020 American Transplant Congress
Impact and Outcomes of Primary Cytomegalovirus Infection in Seronegative Abdominal Solid Organ Transplant Recipients of Cytomegalovirus Unexposed Donors (D-/R-)
M. Jorgenson¹, M. Hillis¹, N. Friedlander¹, A. Gracon², D. Yang², G. Leverson², J. Smith², R. Redfield²
¹UWHC, Madison, WI, ²UWMF, Madison, WI
*Purpose: Primary cytomegalovirus infection (CMV) in high risk (D+/R-) abdominal solid organ transplant recipients (aSOTRs) is well described, however there is a paucity of literature…
2020 American Transplant Congress
Ehrlichiosis Infection Presenting as Thrombotic Microangiopathy Early after Kidney Transplantation
W. Hassan¹, M. Talwar², V. Balaraman², B. Wall¹, M. Molnar¹
¹Medicine-Nephrology, University of Tennessee Health Science Center, Memphis, TN, ²Department of Surgery, Transplant Surgery, Methodist University Hospital, James D Eason Transplant Institute, Memphis, TN
*Purpose: Fever of unknown origin and clinical picture of Thrombotic MicroAngiopathy (TMA) are diagnostic challenges in the early period after kidney transplantation. Here we present…
2020 American Transplant Congress
Outcome of Hepatitis B Virus DNA-Positive Liver Transplantation in Hepatitis B Virus/Hepatitis D Virus Co-Infected Recipient Treated with High Dose Hepatitis B Immune Globulin: A Case Report
M. B. Hammami¹, M. Haris¹, L. Toman¹, N. Danis¹, B. Saberi², E. King³, J. Garonzik-Wang³, B. Philosophe³, A. M. Cameron³, A. Gurakar¹
¹Gastroenterology and Hepatology, Johns Hopkins, Baltimore, MD, ²Gastroenterology and Hepatology, Icahn School of Medicine at Mount Sinai, New York, NY, ³Transplant Surgery, Johns Hopkins, Baltimore, MD
*Purpose: Introduction: While common in Asian countries, liver transplantation (LT) for patients with hepatitis B virus (HBV)/hepatitis D virus (HDV) co-infection is rare in the…
2020 American Transplant Congress
Effectiveness and Tolerability of Cidofovir for the Management of BK Viremia in Kidney Transplant Recipients
M. Thornberg¹, J. Hedvat¹, N. Lange¹, C. Brennan², D. Salerno¹, D. Tsapepas²
¹NewYork-Presbyterian Hospital, Department of Pharmacy, New York, NY, ²Columbia Irving University Medical Center, Department of Transplant Surgery, New York, NY
*Purpose: BK viremia (BKV) is a common complication after kidney transplantation (KT) that often leads to graft dysfunction and loss. Without consensus management guidelines and…
2020 American Transplant Congress
Association between Ezetimibe Usage and Hepatitis C RNA Levels in Uninfected Kidney Transplant Recipients Who Received Hepatitis C Infected Kidneys
A. Azhar, M. Yazawa, M. Talwar, V. Balaraman, A. Bhalla, U. A. Agbim, B. Maliakkal, J. P. Kothadia, S. Nair, J. D. Eason, M. Z. Molnar
James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN
*Purpose: Our previous data showed that transplantation of kidneys from hepatitis C virus (HCV) infected donors to HCV negative recipients achieved excellent short-term graft function,…
2020 American Transplant Congress
Glecaprevir-Pibrentasvir Effect on Tacrolimus Troughs in Abdominal Transplant Recipients
M. Chunduru, K. Schnelle, H. Winters, O. Witkowsky, L. Von Stein
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Glecaprevir-pibrentasvir (GP) is one of several pangenotypic therapies available for the treatment of hepatitis C. Historical use of ritonavir based hepatitis C therapies increased…
2020 American Transplant Congress
Evaluation of an Intervention to Reduce Underdosing of Valganciclovir for Primary Prophylaxis of Cytomegalovirus Infection in Donor Seropositive/Recipient Seronegative Kidney and Liver Transplant Recipients
L. Al Bizri¹, Z. S. Chaudhry², A. Vahia², J. Williams², J. C. Lemos-Ramirez³, B. Summers⁴, A. Patel⁵, S. Nagai⁶, O. Abreu Lanfranco², M. Ramesh², R. Del Busto², G. Alangaden²
¹Internal Medicine, Henry Ford Health System, Detroit, MI, ²Infectious Disease, Henry Ford Health System, Detroit, MI, ³Department of Transplant Infectious Disease, Memorial Regional Hospital, Hollywood, FL, ⁴Central Pharmacy, Henry Ford Health System, Detroit, MI, ⁵Nephrology, Henry Ford Health System, Detroit, MI, ⁶Surgery Transplant, Henry Ford Health System, Detroit, MI
*Purpose: Valganciclovir (VCV) prophylaxis is used to prevent primary cytomegalovirus (CMV) infection in CMV donor seropositive/recipient seronegative (D+/R-) solid organ transplant recipients (SOT). We examined…
2020 American Transplant Congress
Next-Generation Sequencing to Assess Cytomegalovirus Viral Populations During the Course of CMV Infection
G. Elhelou¹, R. Razonable²
¹Medicine, Division of Infectious Diseases and Global Medicine, University of Florida, Gainesville, FL, ²Medicine, Division of Infectious Disease, Mayo Clinic, Rochester, MN
*Purpose: Resistant Cytomegalovirus (CMV) infection has emerged to cause significant impact on morbidity and mortality after solid organ transplantation (SOT). There is limited data on…
2020 American Transplant Congress
De Novo Malignancy after Liver Transplantation for Alcoholic Cirrhosis: Incidence and Outcomes
M. M. Pascale, E. Nure, G. Bianco, F. Frongillo, S. Agnes
Transplant Unit, Fondazione "Policlinico A. Gemelli" UCSC - Rome, Roma, Italy
*Purpose: De novo malignancy, frequent liver transplant (LT) complication, is one of the long-term major causes of mortality. Risk factors are related to immunosuppressive status,…